Milestone Pharmaceuticals (NASDAQ:MIST) Raised to “Hold” at Wall Street Zen

Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Other equities research analysts have also issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. Wells Fargo & Company increased their target price on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of Milestone Pharmaceuticals in a research note on Tuesday, January 6th. Finally, Zacks Research lowered shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $8.00.

Milestone Pharmaceuticals Stock Performance

Shares of NASDAQ MIST opened at $1.04 on Friday. The stock has a market cap of $88.58 million, a price-to-earnings ratio of -1.32 and a beta of 0.48. The company has a current ratio of 8.01, a quick ratio of 8.24 and a debt-to-equity ratio of 1.37. Milestone Pharmaceuticals has a 1-year low of $0.63 and a 1-year high of $3.06. The stock’s 50-day moving average is $1.72 and its 200 day moving average is $1.97.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its earnings results on Friday, March 20th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. The firm had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $37.52 million. On average, sell-side analysts anticipate that Milestone Pharmaceuticals will post -0.62 EPS for the current fiscal year.

Insider Buying and Selling at Milestone Pharmaceuticals

In other news, CEO Joseph Oliveto sold 34,523 shares of the firm’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $1.93, for a total value of $66,629.39. Following the transaction, the chief executive officer owned 482,744 shares in the company, valued at approximately $931,695.92. This trade represents a 6.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 113,693 shares of company stock worth $233,347 over the last ninety days. Corporate insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sapient Capital LLC purchased a new stake in Milestone Pharmaceuticals during the 3rd quarter valued at $25,000. Strategic Family Wealth Counselors L.L.C. purchased a new position in shares of Milestone Pharmaceuticals in the fourth quarter valued at about $25,000. Eaton Financial Holdings Company LLC purchased a new position in shares of Milestone Pharmaceuticals in the fourth quarter valued at about $26,000. Bank of America Corp DE raised its stake in shares of Milestone Pharmaceuticals by 200,550.0% during the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after acquiring an additional 16,044 shares during the last quarter. Finally, Stephenson & Company Inc. bought a new position in shares of Milestone Pharmaceuticals during the third quarter valued at about $40,000. 86.18% of the stock is currently owned by institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.